Algert Global’s Vanda Pharmaceuticals VNDA Stock Holding History

Algert Global’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34,934	Closed	-$174K	–	1335
2025 Q3	$174K	Buy	+34,934	New	+$162K	﹤0.01%	1051
2025 Q2	–	Sell	-26,910	Closed	-$124K	–	1361
2025 Q1	$124K	Buy	+26,910	New	+$125K	﹤0.01%	1119
2022 Q4	–	Sell	-11,830	Closed	-$117K	–	1303
2022 Q3	$117K	Buy	+11,830	New	+$125K	0.01%	1097
2019 Q1	–	Sell	-76,204	Closed	-$1.99M	–	396
2018 Q4	$1.99M	Buy	+76,204	New	+$1.79M	0.56%	43
2017 Q2	–	Sell	-18,223	Closed	-$255K	–	356
2017 Q1	$255K	Buy	18,223 +1,927	+12%	+$27.5K	0.07%	275
2016 Q4	$260K	Buy	+16,296	New	+$262K	0.07%	278
2013 Q4	–	Sell	-26,733	Closed	-$293K	–	389
2013 Q3	$293K	Sell	26,733 -139,901	-84%	-$1.49M	0.08%	276
2013 Q2	$1.35M	Buy	+166,634	New	+$1.12M	0.42%	91

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

Algert Global's VNDA Position: Q4 2025 in Review

Algert Global sold out of Vanda Pharmaceuticals (VNDA) in Q4 2025, closing a stake of 34,934 shares — an estimated $174K sold.

Algert Global first reported a position in VNDA in Q2 2013 and held it in 8 quarters. The position peaked at $1.99M in Q4 2018. 153 funds tracked by Wall St. Rank hold VNDA as of Q4 2025.

Algert Global reported no remaining Vanda Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Algert Global sold 34,934 Vanda Pharmaceuticals shares in Q4 2025, an estimated $174K.
Algert Global first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Algert Global's Vanda Pharmaceuticals position peaked at $1.99M in Q4 2018.
153 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.